CHESTERBROOK, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2021, prior to the market open on Thursday, March 31st, 2022.
Trevena to Release Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
